Natco Pharma won another battle in its quest to knock down patent barriers to its generic drugs, this time for a version of the Gilead Sciences' influenza treatment, Tamiflu (oseltamivir).
Mindera, the developer of a microneedle-based molecular diagnostic system for skin cancer, was among the first 10 resident companies at Johnson & Johnson's just-opened JLABS life science incubator in San Francisco. That means that the life science bigwig believes Mindera's technology is novel and of interest to one of the many companies under its umbrella.
Dara BioSciences is the new marketer of the only orally dissolving buccal tablet approved for oral thrush, which occurs when the Candida albicans fungus grows in the lining of the mouth.
Cancer diagnostics has long been defined by the aim of providing "personalized" and "precision" medicine to patients. But now the buzzword of the moment seems to be trending more toward "universal"--as the industry strives for an all-encompassing test that will mete out the best possible individual treatment protocols based on genomic data.
Researchers at Ireland's Waterford Institute of Technology have been awarded nearly $1 million to test and develop transdermal medications for conditions such as non-melanoma skin cancer.
Hanmi Pharmaceutical has signed a licensing agreement for Kinex Pharmaceuticals to develop its Orascovery pump inhibitor for gastrointestinal treatments in India.
Investigators have begun testing new drugs that can specifically hunt down and eliminate senescent cells in mice, opening the door to what they say could be a new class of therapeutics that promise to one day slow down the human aging process.
Canadian CRO conglomerate Altasciences struck a deal with preclinical researcher ITR Laboratories, joining forces to create a discovery-to-development offering for drugmakers.
Want Sovaldi (sofosbuvir), the hepatitis C drug selling in the United States for $1,000 per pill, for just $10 a pill? Go to Bangladesh or some other country where the drug is about to be produced and sold free of the control of Sovaldi's owner, Gilead Sciences.
Biotech companies got a boost in Japan on Friday as it was announced that SanBio will be listed publicly on the Tokyo Stock Exchange beginning April 8.